Baynes Roy D.

Director Roy D. Baynes sold 32,750 shares (46.6% of holdings) for $1,352,130 at $41.07–$42.12 on 2026-04-14.

Roy D. Baynes, a Director at Travere Therapeutics, executed 2 separate sales totaling 32,750 shares for $1,352,130, reducing his stake from 70,250 to 37,500 shares. The sales occurred at $41.07 and $42.12 per share, near the 52-week high of $42.13 and above the current price of $39.54. Across his prior open-market activity, Baynes's cross-ticker track record shows a 57.14% well-timed rate on 14 prior sells (with average 90-day returns of +5.4%), though this historical accuracy is not ticker-specific. The company's fundamentals show annual revenue growth of +110.4% and net income of $25.7M in the latest quarter, though full-year results remain negative; valuation stands at P/E 17.57 and market cap $3.6B.

Director Roy D. Baynes sold 12,780 shares at $213.47–$224.89 for $2.8M, reducing stake 41.0% to 18.4K shares as stock nears 52-week high of $230.63.

Director Roy D. Baynes executed 8 separate sales totaling 12,780 shares for $2,809,688.62 over two trading days (2025-11-19 through 2025-11-20), selling at prices ranging from $213.47 to $224.89 with a blended average of $219.85. This transaction reduced his holdings by 41.0% from 31.1K shares to 18.4K shares. The stock's 30-day and 90-day gains of +22.7% and +39.3% respectively stand in contrast to his prior five sales at NTRA, all on 2024-11-15, which each produced positive 90-day returns (+12.0% to +18.4%), indicating those prior sales were poorly timed as subsequent prices rose. His cross-ticker track record shows an average 90-day well-timed rate of 0.00%, suggesting he has not demonstrated an ability to sell ahead of declines. The company remains unprofitable with net income of -$87.5M despite strong 56.8% annual revenue growth, a dynamic that may influence portfolio composition decisions.

Director Roy D. Baynes sold 37,230 shares at blended $146.11; post-sale holdings drop to 15,807 shares (-70.2%)

On 2024-11-15, Director Roy D. Baynes executed 6 separate sales totaling 37,230 shares for $5,439,564.60, with individual transaction prices ranging from $144.26 to $149.98 and a blended average price of $146.11. This sale reduced his holdings from 53,037 shares to 15,807 shares, representing a -70.2% reduction in his stake. Natera is a high-growth unprofitable company (annual revenue growth of +32.0% but negative full-year net income of $-31,592,000.00) trading near its 52-week high; the stock is -9.3% from its $160.97 peak but up +15.2% over the past 30 days and +17.8% over 90 days. The substantial reduction in director-level holdings warrants investor attention given the company's pre-profitability stage, though the timing relative to the stock's strong recent momentum does not establish a clear forward-looking signal without additional context on Baynes' longer-term trading patterns at this issuer.